Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ion TabarnafiledCriticalIon Tabarna
Priority to MDA20010117ApriorityCriticalpatent/MD1732G2/en
Publication of MD1732F1publicationCriticalpatent/MD1732F1/en
Publication of MD1732G2publicationCriticalpatent/MD1732G2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention refers to medicine, namely, to therapy and gastroenterology. Summary of the invention consists in that there are determined the patient's age, heredity, blood group, body mass deficit, pain syndrom intensity, it is carried out an atropinic test and it is endoscopic determined localization, dimension, time of cicatrisation of the ulcerous defect, as well as the gastritis and/or bulbitis form. The obtained data receive the corresponding values which are summed up, thereafter according to the obtained values sum the variant of the duodenal ulcerous disease evolution is prognosticated.Claims: 1
MDA20010117A2001-05-022001-05-02Method of prognosticating the duodenal ulcerous disease evolution
MD1732G2
(en)
Hyperbranched amylopectin for use in methods for surgical or therapeutic treatment of mammals or in diagnostic methods, especially for use as a plasma volume expander